Alcon Inc. introduced its new one‑week replacement contact lens, PRECISION7, in Canada on February 2 2026. The lens is available in sphere and toric options and is the first in Alcon’s lineup to feature the company’s ACTIV‑FLO System 2.5, which delivers continuous surface moisturization for up to 16 hours of comfort and clear vision even on the seventh day of wear.
PRECISION7’s design blends the convenience of a weekly lens with the comfort of a daily disposable. The ACTIV‑FLO System 2.5 maintains a moist, stable surface, reducing dryness and irritation while preserving optical clarity. The lens’s water‑gradient material and silicone‑hydrogel core provide a soft, breathable wear experience that supports extended use without compromising visual acuity.
The launch targets patients who prefer a weekly replacement schedule but are sensitive to cost. By offering an intuitive start‑date option—any day of the week—PRECISION7 fills a niche between daily disposables, which are favored by eye‑care professionals, and other weekly lenses that may lack the same level of moisture retention. Alcon expects the product to broaden its share of the Canadian contact‑lens market, where cost‑conscious consumers often opt for reusable lenses.
PRECISION7 is part of Alcon’s broader WaterInnovations portfolio, which also includes DAILIES TOTAL1, PRECISION1, and TOTAL30. Alcon’s annual revenue stands at $10.19 billion, with a market valuation near $40 billion. The new lens adds a higher‑margin segment to the company’s vision‑care lineup, supporting long‑term growth in a competitive market that includes daily disposables and other weekly options.
"Having an option like PRECISION7, that aligns naturally with how patients think about time and replacement can make a meaningful difference in their overall contact‑lens wearing experience," said Dr. Kenton Fredlund, optometrist at FYidoctors. Vanessa Johari Hansen, Country Business Unit Head for Vision Care at Alcon Canada, added, "The launch of PRECISION7 reaffirms our commitment to improving the patient experience with impactful innovation." No immediate market reaction data were reported following the announcement.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.